Skip to main content
. 2023 Jun 15;25:31. doi: 10.1186/s12968-023-00941-0

Table 1.

Patient characteristics

All Patients
(n = 215)
COA with BAV
(n = 145)
COA with TAV
(n = 70)
p value
Age, years 25.3 (18.8, 34.3) 25.7 (1.3,34.3) 24.5 (17.7, 34.3) 0.75
Gender, male, n (%) 121 (56) 85 (59) 36 (51) 0.38
BSA, m2 1.8 (1.6, 2) 1.8 (1.6, 2) 1.8 (1.6, 2) 0.89
Type of BAV, n (%)
 Left-right fusion 125 (86)
 Right-non fusion 17 (12)
 Left-non fusion 3 (2)
Age at COA treatment, years 1.7(0.1, 6.9) 1.1(0.1, 1.1) 2.4 (0.1, 10.2) 0.37
Treatment modality, n (%) 0.72
 Surgery 183 (85) 125 (86) 58 (84)
 Balloon dilation 18 (8) 12 (8) 6 (9)
 Stent 14 (7) 8 (6) 6 (9)
Type of surgical repair, n (%) 0.37
 End-to-end repair 107 (59) 77 (62) 30 (51)
 Subclavian flap 25 (14) 15 (12) 10 (17)
 Patch reconstruction 13 (7) 6 (5) 7 (12)
 Interposition graft 8 (4) 5 (4) 3 (5)
 Extended end-to-end repair 1 (0.5) 1 (1) 0
 Unavailable surgical record* 29 (16) 21 (17) 8 (14)
 > Mild aortic regurgitation, n (%) 11(5) 11 (8) 0 0.02
 > Mild aortic stenosis, n (%) 7 (3) 7 (5) 0 0.10
Medication use, n (%)
 β-blocker 33 (16) 18 (12) 15 (21) 0.11
 ACE inhibitor 43 (20) 28 (19) 15 (21) 0.72
 Hydrochlorothiazide 10 (5) 9 (6) 1 (1) 0.17
 Angiotensin receptor blocker 9 (4) 9 (6) 0 0.03
 Calcium channel blocker 8 (4) 5 (3) 3 (4) 0.72

Data are presented as number (percent) or median (IQR range)

BSA body surface area, BAV bicuspid aortic valve, COA Coarctation of the aorta, ACE angiotensin-converting enzyme, TAV tricuspid aortic valve

*In a minority of patients whose initial surgical repair was at another institution, surgical records were not available to confirm details